SCHEDULE: Andrew Van Vurst Boosts BioStem Stake to 18.4%

Andrew Van Vurst reports beneficial ownership of 3,854,452 shares, representing 18.4% of BioStem Technologies, Inc. common stock, primarily through vested options and direct holdings.

Summary

• Andrew Van Vurst has reported beneficial ownership of 3,854,452 shares of BioStem Technologies, Inc. common stock.
• This holding represents 18.4% of the total outstanding shares.
• The reported shares include directly held stock, shares from exercised vested options, and shares from partially vested options.
• The filing also notes shares issuable upon conversion of preferred shares.
• Certain restricted stock units and unvested options are excluded from the reported beneficial ownership.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating significant beneficial ownership by a key individual, which can signal confidence and alignment with company performance.

Positives

• Significant beneficial ownership by Andrew Van Vurst (18.4%) suggests strong conviction in the company's prospects.
• The majority of the reported shares are derived from vested options, indicating past performance or commitment.
• The filing details specific option grants and their vesting schedules, providing transparency.

Negatives

• The filing does not contain financial performance data, making it difficult to assess the company's operational health.
• A substantial portion of the reported ownership is tied to options, which are contingent on future exercise and potential market conditions.

Risks

• The value of the reported shares is subject to the future performance and stock price of BioStem Technologies, Inc.
• The exclusion of unvested options and RSUs means a significant portion of potential future ownership is not yet realized and is subject to vesting conditions.
• Reliance on derivative securities (options) for a large part of the beneficial ownership introduces leverage and potential volatility.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• Andrew Van Vurst certifies that the information set forth in this statement is true, complete and correct.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and individuals who acquire a significant stake in a company. This filing indicates a substantial personal investment by Andrew Van Vurst in BioStem Technologies, Inc., which can be interpreted as a positive signal of confidence by an insider.

Stakeholder Impact

• Shareholders may view this increased insider ownership positively, potentially signaling confidence in the company's future.
• Employees with stock options may be encouraged by the significant stake held by a key individual.
• Creditors and suppliers may see this as a sign of stability, though the filing lacks direct financial performance indicators.

Next Steps

• Andrew Van Vurst will continue to hold and potentially exercise vested options.
• The company's performance will dictate the future value of the reported shares and options.

Key Dates

Keywords

Beneficial Ownership, Schedule 13G, Andrew Van Vurst, BioStem Technologies, Common Stock, Vested Options, Insider Holding